AFRICAN AMERICAN ANTIPLATELET STROKE PREVENTION STUDY (AAASPS)

该提案是一项多中心随机双盲试验， 意向治疗分析，以检验噻氯匹定的疗效 盐酸盐与阿司匹林在复发性癫痫二级预防中的比较 中风、血管性死亡和心肌梗死的发病率 患有非心源性栓塞性缺血性卒中的老年非裔美国患者。 该试验还将研究不良经历的差异， 噻氯匹定与阿司匹林在非裔美国人中的安全性特征 非心源性缺血性卒中患者。 审判将在 在中年人口较多的芝加哥地区 老年非裔美国人 这项试验很重要，因为非洲裔美国人承受着过度的负担， 不同种族和民族的卒中风险和卒中死亡率比较 在美国的团体。 非洲裔美国人和其他少数民族一直被 在生物医学研究中代表性不足，而且没有大规模的 主要关注中风二级预防的临床试验 在非裔美国人中。 从非白人， 在噻氯匹定阿司匹林卒中中，主要是非洲裔美国患者 研究（塔斯）表明，噻氯匹定比阿司匹林更有效， 中风和死亡的二级预防，非致命性和致命性 中风 严重不良事件的风险也很低， 在接受噻氯匹定的组中与接受噻氯匹定的组 用阿司匹林治疗。

The proposal is a multi center randomized double blind trial using intention to treat analyses to test the efficacy of ticlopidine hydrochloride versus aspirin in the secondary prevention of recurrent stroke, vascular death and myocardial infarction among middle aged and elderly African American patients with non-cardioembolic ischemic stroke. The trial will also study differences in adverse experiences and the safety profile between ticlopidine and aspirin in the African American non-cardioembolic ischemic stroke patients. The trial will be conducted in teh Chicago area which has a large population of middle aged and elderly African Americans. The trial is important as African Americans suffer an excess burden of stroke risk and stroke mortality as compared to toher racial and ethnic groups in the US. African Americans and other minorities have been underrepresented in biomedical research, and there has been no large scale clinical trial that has focused primarily on secondary stroke prevention in African Americans. Preliminary data collected from nonwhite, predominantly African American patients, in the Ticlopidine Aspirin Stroke Study (TASS) suggest that ticlopidine is more effective than aspirin in the secondary prevention of stroke and death, and nonfatal and fatal stroke. The risk of serious adverse events was also low and did not differ substantially in the group receiving ticlopidine from the group treated with aspirin.